Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...

Chinese researchers have achieved a significant breakthrough by efficiently creating monkey blastoids using stem cells, ...

Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

Despite these advancements, the team acknowledged that further optimization is needed, particularly in improving the functionality of trophoblast cells within the blastoid capsules. Future ...

Cardinal Health announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully ...

In what marks a significant leap forward in precision oncology, the TROP2 (trophoblast cell surface antigen 2) antibody market is witnessing an accelerated growth in clinical trials and ...

Melatonin promotes EMT in trophoblast cells via GDF15-mediated activation of the SMAD2/3 pathway and partially induces the expression of GPX4 through GDF15 to enhance oxidative damage resistance ...

Melatonin promotes EMT in trophoblast cells via GDF15-mediated activation of the SMAD2/3 pathway and partially induces the expression of GPX4 through GDF15 to enhance oxidative damage resistance ...

Disruptions in αVβ3 function may contribute to conditions such as HDFN, where immune responses can affect fetal health.